WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.
WHOs Normative Work in the Field of Pharmaceuticals - introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines Essential.
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
Prequalification and Quality Monitoring of anti-malaria products Andre van Zyl, M. Pharm. Project Manager Health Technology and Pharmaceuticals Cluster,
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
1 Department of Essential Medicines and Pharmaceutical Policies, Health Systems and Services World Health Organization's Prequalification Program for medicines.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
Short Update WHO Essential Medicines and Health products IPC Meeting 4 to 6 June 2014.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
WHO Traditional Medicine Strategy and Guidelines Dr Arvind Mathur MD, DHA, DNB Cluster Coordinator Family & Community Health WHO-India World Health Organisation.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
INTRODUCTION TO RA.
Bioequivalence and Bioavailability Working Group.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM)
Regulation of medicines and other health technologies. The future of regulation, where are we going? EMP TBS November 2014, Geneva Dr Lembit Rägo Head,
OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23,
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
ACCESS TO MEDICINES - POLICY AND ISSUES
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
1 Department of Essential Medicines and Pharmaceutical Policies Introduction to Medicines Quality Assurance and Safety Dr Lembit Rägo Coordinator Quality.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
WHO Prequalification Programme Milan Smid, M.D., Ph.D. Prequalification Programme: Priority Essential Medicines.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
1 Department of Essential Medicines and Pharmaceutical Policies Medicines Regulation: Introduction Dr Lembit Rägo Coordinator Quality Assurance and Safety:
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
DIA Clinical Safety and Pharmacovigilance Community
WHO Medicines Work in Countries: The Kenya Example
Quality of Medicines: Introduction Tuesday, 17 November 2009
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Overview of vaccines prequalification
Quality Assurance and Safety of Medicines
GDF Quality Assurance Processes
Medicines Regulation: Introduction
Quality Problems with Antimalarials
Prequalification of essential medicines
National Medicines Policies
Drug regulation and quality assurance:
Assessment of Medicines
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Vigilance of medical devices and IVDs in the South East Asia Region –Safety Monitoring Systems in India and other Countries Dr. Madhur Gupta; MD, DM Technical.
Prequalification of HIV/AIDS products and manufacturers
Quality Assurance and Safety of Medicines
Pharmacovigilance.
National Medicines Policies
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction EDM Technical Briefing 2004 Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals Cluster World Health Organization E-mail: ragol@who.ch

Why medicines are special category of products? Consumers, patients and health care workers have limited capacity to judge there SAFETY QUALITY EFFICACY

Are all medicines safe, effective and meet quality criteria? No, they are not Some are safe, but not effective or necessarily meet the quality criteria Some may be effective, meet quality criteria but are not safe Some meet quality criteria but are not necessarily safe or have any efficacy

Quality - Safety Some safety parameters are determined by quality Some safety parameters are determined by the intrinsic properties of active pharmaceutical ingredient

What type of medicines we have? Originator products Multisource (generic) products KEY – INTERCHANGEABILITY, more important THERAPEUTIC INTERCHNGEABILITY ALL LITERATURE IS BASED ON ORGINATORS No interchangeability – NEED FOR NEW SAFETY and EFFICACY DATA, NEW BOOKS HAVE TO BE WRITTEN

What type of regulations exist and how they differ? For innovator products proof of QUALITY, SAFETY and EFFICACY is needed For multisource products QUALITY, safety and efficacy data is referred to the originator providing only evidence about interchangeability (bioequivalence, clinical testing, in limited cases dissolution data)

Regulations: Global vs National National regulations still differ a lot What is ICH and what it is not? Regional harmonization initiatives Do global norms exist for generics?

Is quality of medicines a problem? Yes, a HUGE problem If we would have the same compliance with norms and quality in aircraft industry Globally approximately 25% planes would not take off the grounds 10% would crash and kill the people (treatment failure = killing in some cases; toxicity etc. )

What WHO is doing? Norms and standards, nomenclatures International Pharmacopoeia International Nonproprietary Names (INN) ATC/DDD classification … Regulatory guidelines Good Manufacturing Practice; Good Clinical Practice etc. Comprehensive set of guidelines for registering generic drugs Information exchange WHO Drug Information (quarterly) WHO pharmaceutical Newsletter WHO Rapid Alerts International Conference of Drug Regulatory Authorities (ICDRA) – usually more than 100 countries represented …. Capacity building and training GMP training courses Courses on how to assess generic drugs Courses on pharmacovigilance

Conclusions A lot of good work ongoing but …. Limited capacity to advertise, promote, inform etc. Limited resources to build capacity in countries Please, for more information: http://www.who.int/medicines